Dana-Farber's Antonia Giordano, MD, PhD shares new data on a novel CDK4-selective inhibitor in como with letrozole as 1st line treatment in HR+/HER2 Metastatic Breast Cancer.
Related Presenters
Antonio Giordano, MD Giordano, PhD
Assistant Professor of Medicine, Harvard Medical School
Dr. Giordano completed his medical school and oncology fellowship at University of Naples Federico II in Italy in 2004 and 2009, respectively. The passion for research was the motivation behind his pursuit of starting a PhD Program in ...
